Literature DB >> 23943339

Periprocedural coagulability in patients undergoing ablation of atrial fibrillation: lessons from a periablation anticoagulation strategy of a brief withdrawal of warfarin without heparin bridging.

Akinori Sairaku1, Yukihiko Yoshida, Haruo Hirayama, Yukiko Nakano, Yasuki Kihara.   

Abstract

We aimed to examine what becomes of the coagulable state when warfarin is interrupted in patients undergoing ablation of atrial fibrillation (AF). We studied 62 patients with a CHADS2 score of 0 or 1 who underwent ablation for paroxysmal AF. Warfarin was discontinued the day before the ablation without heparin-bridging, and intravenous heparin was administered during the procedure in a conventional manner, and warfarin was then resumed after achieving hemostasis of the access site. The international normalized ratio (INR) values or D-dimer levels were measured at five different time points during the periprocedural period, and the periprocedural hemorrhagic and thromboembolic complications were assessed. The INR value constantly decreased after withdrawal of warfarin, and did not recover to the level before its discontinuation at the time of hospital discharge despite a short interruption of warfarin (mean ± SD, 1.75 ± 0.52 to 1.41 ± 0.27, p < 0.0001). However, the D-dimer level continued to increase over a period of 48 h after the ablation in spite of the administration of a sufficient amount of heparin during the procedure and a quick resumption of warfarin (mean ± SD, 0.57 ± 0.19 to 0.85 ± 0.36 μg/mL, p < 0.0001). The INR value measured just before the ablation had a significant inverse correlation to the D-dimer levels assessed just before (r = -0.304), immediately after (r = -0.440), 24 h after (r = -0.442) and 48 h after the ablation (r = -0.463). In conclusion, the risk of hyper-coagulability may increase during the early postprocedural period of AF ablation in patients who were inappropriately anticoagulated with warfarin.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 23943339     DOI: 10.1007/s11239-013-0982-0

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  22 in total

1.  Increased hemostatic molecular markers in patients undergoing anticoagulant therapy.

Authors:  H Wada; H Ikuma; Y Mori; M Shimura; K Hiyoyama; T Nakasaki; K Onoda; N Yamada; T Ohta; J Nishioka; N Sakuragawa; H Shiku
Journal:  Semin Thromb Hemost       Date:  2000       Impact factor: 4.180

Review 2.  Warfarin withdrawal. Pharmacokinetic-pharmacodynamic considerations.

Authors:  G Palareti; C Legnani
Journal:  Clin Pharmacokinet       Date:  1996-04       Impact factor: 6.447

3.  Fibrin D-dimer and beta-thromboglobulin as markers of thrombogenesis and platelet activation in atrial fibrillation. Effects of introducing ultra-low-dose warfarin and aspirin.

Authors:  G Y Lip; P L Lip; J Zarifis; R D Watson; D Bareford; G D Lowe; D G Beevers
Journal:  Circulation       Date:  1996-08-01       Impact factor: 29.690

4.  Rapid hemostasis at the femoral venous access site using a novel hemostatic pad containing kaolin after atrial fibrillation ablation.

Authors:  Akinori Sairaku; Yukiko Nakano; Noboru Oda; Yuko Makita; Kenta Kajihara; Takehito Tokuyama; Yasuki Kihara
Journal:  J Interv Card Electrophysiol       Date:  2011-02-19       Impact factor: 1.900

5.  Periprocedural stroke and management of major bleeding complications in patients undergoing catheter ablation of atrial fibrillation: the impact of periprocedural therapeutic international normalized ratio.

Authors:  Luigi Di Biase; J David Burkhardt; Prasant Mohanty; Javier Sanchez; Rodney Horton; G Joseph Gallinghouse; Dhanunjay Lakkireddy; Atul Verma; Yaariv Khaykin; Richard Hongo; Steven Hao; Salwa Beheiry; Gemma Pelargonio; Antonio Dello Russo; Michela Casella; Pietro Santarelli; Pasquale Santangeli; Paul Wang; Amin Al-Ahmad; Dimpi Patel; Sakis Themistoclakis; Aldo Bonso; Antonio Rossillo; Andrea Corrado; Antonio Raviele; Jennifer E Cummings; Robert A Schweikert; William R Lewis; Andrea Natale
Journal:  Circulation       Date:  2010-06-01       Impact factor: 29.690

6.  Atrial fibrillation ablation in patients with therapeutic international normalized ratio: comparison of strategies of anticoagulation management in the periprocedural period.

Authors:  Oussama M Wazni; Salwa Beheiry; Tamer Fahmy; Conor Barrett; Steven Hao; Dimpi Patel; Luigi Di Biase; David O Martin; Mohamed Kanj; Mauricio Arruda; Jennifer Cummings; Robert Schweikert; Walid Saliba; Andrea Natale
Journal:  Circulation       Date:  2007-11-12       Impact factor: 29.690

7.  Prediction of left atrial appendage thrombi in non-valvular atrial fibrillation.

Authors:  Seiji Habara; Keigo Dote; Masaya Kato; Shota Sasaki; Kenji Goto; Hiroaki Takemoto; Daiji Hasegawa; Osamu Matsuda
Journal:  Eur Heart J       Date:  2007-08-22       Impact factor: 29.983

8.  Complete isolation of left atrium surrounding the pulmonary veins: new insights from the double-Lasso technique in paroxysmal atrial fibrillation.

Authors:  Feifan Ouyang; Dietmar Bänsch; Sabine Ernst; Anselm Schaumann; Hitoshi Hachiya; Minglong Chen; Julian Chun; Peter Falk; Afsaneh Khanedani; Matthias Antz; Karl-Heinz Kuck
Journal:  Circulation       Date:  2004-10-04       Impact factor: 29.690

9.  Temporary discontinuation of warfarin therapy: changes in the international normalized ratio.

Authors:  R H White; T McKittrick; R Hutchinson; J Twitchell
Journal:  Ann Intern Med       Date:  1995-01-01       Impact factor: 25.391

10.  Rebound after cessation of oral anticoagulant therapy: the biochemical evidence.

Authors:  U Genewein; A Haeberli; P W Straub; J H Beer
Journal:  Br J Haematol       Date:  1996-02       Impact factor: 6.998

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.